StatPearls

Related Articles

StatPearls

Book. 2018 01

Authors:

Abstract
Selegiline, a monoamine oxidase (MAO) inhibitor, is FDA-approved as an adjunct treatment in the management of patients with Parkinson disease and as a treatment for a major depressive disorder (MDD) in adults. Selegiline is also used off-label for early Parkinson disease,[1] and the treatment of attention-deficit/hyperactivity disorder (ADHD).[2]

PMID: 30252350

via https://www.ncbi.nlm.nih.gov/pubmed/30252350?dopt=Abstract